Enrollment Complete for Clinical Trial of LymPro, an Alzheimer’s Investigational Blood Diagnostic Test

Enrollment Complete for Clinical Trial of LymPro, an Alzheimer’s Investigational Blood Diagnostic Test
The second part of a clinical study evaluating the use of a blood diagnostic test for Alzheimer's disease — called the Lymphocyte Proliferation Test (LymPro Test) — is now fully enrolled, the trial's sponsor, Breakthrough Diagnosticsannounced. The trial is ongoing at Leipzig University in Germany, and top-line results are expected in the first quarter of 2020. LymPro measures markers of immune cells present in the blood as a surrogate for loss of nerve cell function and the toxic accumulation of beta-amyloid plaques in the brain, which is a hallmark of Alzheimer's disease. Beta-amyloid, or just amyloid, is one of the prime suspects behind Alzheimer's. The accumulation of amyloid in plaques damages brain nerve cells (neurons), disrupting their communication and eventually causing their death. Some researchers believe that defects in the processes directing the production, accumulation or disposal of beta-amyloid are the primary cause of Alzheimer’s, a theory called “the amyloid hypothesis.” Neuronal damage and death also are thought to result from cellular abnormalities that lead to the
Subscribe or to access all post and page content.